Clinical Report: Inflammatory and Metabolic Changes in Asthma-COPD Overlap
Overview
This study investigates the inflammatory-metabolic profiles associated with asthma-COPD overlap (ACO) compared to COPD. It identifies specific biomarkers that may differentiate ACO from COPD.
Background
Asthma-COPD overlap (ACO) presents a clinical challenge due to its shared characteristics with both asthma and COPD, leading to increased morbidity and healthcare utilization. This study aims to clarify these profiles and identify biomarkers that can aid in differentiating ACO from COPD.
Data Highlights
Biomarker
ACO vs COPD
CTI
Elevated
RCII
Elevated
RFM
Elevated
LAP
Elevated
CALLY
Inversely associated
Key Findings
Participants with ACO had a greater inflammatory-metabolic burden than those with asthma or COPD alone.
Several metabolic biomarkers (CTI, RCII, RFM, LAP) were elevated in ACO compared to COPD.
Inflammatory biomarkers (CLR, NLR, ELR, MLR, SII, SIRI) were associated with ACO in multinomial logistic regression analyses.
LASSO regression identified ELR, MLR, CTI, and CALLY as candidate biomarkers for distinguishing ACO from COPD.
The combined biomarker model showed an AUC of 0.580 for ACO versus COPD.
Clinical Implications
The identification of specific inflammatory and metabolic biomarkers may assist clinicians in differentiating ACO from COPD.
Conclusion
ACO is associated with inflammatory-metabolic alterations compared to COPD. The findings suggest an association between inflammatory-metabolic disturbances and the biological heterogeneity of ACO.
“And when one of these measles cases ends up in a low-immunization community, that's when the ember really has a chance to expand and become a wildfire.”
